An Evening With Experts: Selecting and Sequencing Therapy in HR+/HER2- Metastatic Breast Cancer

Watch this on-demand Webcast on the evolving use of antibody–drug conjugates in the care of patients with advanced breast cancer from Clinical Care Options (CCO)

Prof Michael Untch, MD, PhD
Program Director Javier Cortes, MD, PhD Ian E. Krop, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: November 30, 2020 Expired: November 29, 2021

T-DM1: Setting the Stage for ADC Development in Breast Cancer

Next-Generation HER2-Directed ADCs in Development

ADCs With Other Anti-HER2 Targeting Mechanisms and Beyond HER2 Positive Disease: Expanding Potential Benefit to Other Breast Cancer Subsets

Q&A Session

In this slideset from Clinical Care Options, a panel of international experts review the role of PARP inhibitors for patients with metastatic breast cancer.

Pierfranco Conte, MD Véronique Diéras, MD Mark E. Robson, MD Released: November 24, 2020

Video from Clinical Care Options (CCO) with global perspectives on using PARP inhibitors in the care of patients with metastatic breast cancer

Pierfranco Conte, MD Véronique Diéras, MD Mark E. Robson, MD Released: November 24, 2020

Introduction

BRCA Testing

Using PARPi in MBC

Safety and Tolerability of PARP Inhibitors

PARPi Future Directions

PARPi in MBC: Summary

Commentary by Heather McArthur, MD: clinical implications of FDA approval for pembrolizumab plus chemotherapy in PD-L1–positive advanced TNBC from CCO

Heather McArthur, MD, MPH Released: November 20, 2020